Avastin Macular Edema and Degeneration Market Analysis and Forecast to 2023

RnRMarketResearch.com offers “Avastin (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023”global research report on its store.

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Avastin is active against all isoforms of VEGF-A, and can prevent it from interacting with its receptors on the surface of endothelial cells, which leads to the inhibition of angiogenesis, a key feature of both wAMD and DME. Therefore, in addition to its approved therapeutic role as an oncology drug, Avastin has been used off-label for many years as an IVT anti-VEGF treatment for these retinal diseases, despite the launch of Lucentis (a mAb fragment derived from the same parent murine antibody as Avastin) in 2006 for wAMD, which was also developed by Genentech.

The Complete report is available at http://www.rnrmarketresearch.com/avastin-macular-edema-and-macular-degeneration-forecast-and-market-analysis-to-2023-market-report.html .

Scope of The Report:

  • Overview of Macular Edema and Macular Degeneration, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Avastin including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Avastin for the top seven countries from 2013 to 2023.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to Buy This Report:

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Macular Edema and Macular Degeneration.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of Avastin performance.
  • Obtain sales forecast for Avastin from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan).

Order a purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=312779 .

Table of Content for “Avastin (Macular Edema and Macular Degeneration) – Forecast and Market Analysis to 2023” research report includes:

6 Avastin (bevacizumab) 50

6.1 Overview 50

6.2 Efficacy - Macular Degeneration 53

6.3 Efficacy - Macular Edema 54

6.4 Safety 54

6.5 SWOT Analysis 55

6.6 Forecast 55

1.1 List of Tables

Table 1: ARM System Classification of AMD 19

Table 2: Symptoms of AMD 20

Table 3: National and International Treatment Guidelines for ME and AMD 33

Table 4: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013 34

Table 5: Leading Treatments for ME and AMD, 2014 49

Table 6: Product Profile - Avastin 53

Table 7: Avastin SWOT Analysis, 2014 55

Table 8: Global Sales Forecast ($m) for Avastin, 2013-2023 56

Table 9: Surveyed High-Prescribing Physicians (Non-KOLs), by Country 79

Priced at US $3495 for a single user PDF, a discount on this research report can be requested at http://www.rnrmarketresearch.com/contacts/discount?rname=312779 .

About Us:

RnR Market Research library offers syndicated reports by market research publishers from across the globe. We help you find the most relevant business intelligence from ready-to-buy syndicated market research studies. Not limited to industry reports covering telecommunication, healthcare, pharmaceutical, financial services, energy, technology, real estate, logistics, F&B , media and more, RnR Market Research also offers company data, country profiles, trends, information and analysis on the sector of your interest. (http://www.rnrmarketresearch.com/latest_reports).